Published in Neuromolecular Med on May 25, 2016
The neurobiology of the Prader-Willi phenotype of fragile X syndrome. Intractable Rare Dis Res (2016) 0.75
Chronic 5-Aminoimidazole-4-Carboxamide-1-β-d-Ribofuranoside Treatment Induces Phenotypic Changes in Skeletal Muscle, but Does Not Improve Disease Outcomes in the R6/2 Mouse Model of Huntington's Disease. Front Neurol (2017) 0.75
Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem (2004) 3.00
Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med (2011) 2.87
Calorie restriction mimetics: an emerging research field. Aging Cell (2006) 2.82
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol (1997) 2.64
Dietary restriction normalizes glucose metabolism and BDNF levels, slows disease progression, and increases survival in huntingtin mutant mice. Proc Natl Acad Sci U S A (2003) 2.35
Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet (2008) 1.98
Regulation of mitochondrial fission and apoptosis by the mitochondrial outer membrane protein hFis1. J Cell Sci (2005) 1.75
Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell (2012) 1.74
Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem (2005) 1.67
Mitochondrial loss, dysfunction and altered dynamics in Huntington's disease. Hum Mol Genet (2010) 1.62
Quantification of metformin by the HPLC method in brain regions, cerebrospinal fluid and plasma of rats treated with lipopolysaccharide. Pharmacol Rep (2010) 1.56
A structural view of mitochondria-mediated apoptosis. Nat Struct Biol (2001) 1.54
Mutant huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet (2011) 1.48
An anti-aging drug today: from senescence-promoting genes to anti-aging pill. Drug Discov Today (2007) 1.47
Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett (2006) 1.47
Nuclear translocation of AMPK-alpha1 potentiates striatal neurodegeneration in Huntington's disease. J Cell Biol (2011) 1.30
Mitochondrial membrane dynamics, cristae remodelling and apoptosis. Biochim Biophys Acta (2006) 1.20
Trinucleotide repeat length and clinical progression in Huntington's disease. Neurology (1996) 1.12
Coordinated time-dependent modulation of AMPK/Akt/mTOR signaling and autophagy controls osteogenic differentiation of human mesenchymal stem cells. Bone (2012) 1.04
Mitochondrial function and parental sex effect in Huntington's disease. Lancet (1990) 1.03
Increased mitochondrial fission and neuronal dysfunction in Huntington's disease: implications for molecular inhibitors of excessive mitochondrial fission. Drug Discov Today (2014) 0.97
Huntington's disease, calcium, and mitochondria. Biofactors (2011) 0.96
Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin. PLoS One (2013) 0.92
The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro. Neurobiol Dis (2013) 0.90
AMPK protects proximal tubular cells from stress-induced apoptosis by an ATP-independent mechanism: potential role of Akt activation. Am J Physiol Renal Physiol (2011) 0.90
AMP-activated protein kinase counteracts brain-derived neurotrophic factor-induced mammalian target of rapamycin complex 1 signaling in neurons. J Neurochem (2013) 0.82
Overweight in polycystic ovary syndrome. An update on evidence based advice on diet, exercise and metformin use for weight loss. Minerva Endocrinol (2013) 0.78